帕克替尼在骨髓纤维化中的探索历程
骨髓纤维化可表现为症状性脾大和/或血细胞减少(包括血小板减少),疾病相关血小板减少预后差,中位总生存期不足2年。已获批的JAK1/2抑制剂未在血小板≤50×10^9/L患者中评估,且可能加重血小板减少。帕克替尼(PAC)为选择性JAK2、FLT3、IRAK1多激酶抑制剂,旨在满足该未满足需求。
要点
- 骨髓纤维化相关血小板减少预后差,中位总生存期不足2年。
- 已获批JAK1/2抑制剂未在血小板≤50×10^9/L患者中评估,且可能加重血小板减少。
- 帕克替尼为选择性JAK2、FLT3、IRAK1多激酶抑制剂,获批用于血小板≤50×10^9/L的骨髓纤维化患者。
核心结论
- 帕克替尼获批用于治疗血小板≤50×10^9/L的骨髓纤维化患者。
研究设计与样本
- 帕克替尼在一线治疗(PERSIST-1:帕克替尼400 mg每日一次 vs 最佳可用疗法)和二线治疗(PERSIST-2:帕克替尼400 mg每日一次或200 mg每日两次 vs 最佳可用疗法)的2项随机3期试验中评估,PERSIST-2纳入血小板≤100×10^9/L的骨髓纤维化患者。
主要发现
- PERSIST-1达到主要终点。
- PERSIST-2因临床暂停而提前终止,但达到脾脏缓解终点,并显示症状改善趋势。
- 对PERSIST-1和PERSIST-2的后续仔细审查未证实帕克替尼组严重出血或心脏事件增加。
- 剂量探索PAC203研究支持200 mg每日两次的安全性和有效性。
关键数值与推荐
- PERSIST-1中帕克替尼400 mg每日一次组因出血和心脏事件过多被美国食品药品监督管理局要求临床暂停。
- PERSIST-2纳入血小板≤100×10^9/L的骨髓纤维化患者,帕克替尼400 mg每日一次或200 mg每日两次对比最佳可用疗法。
- PAC203研究支持帕克替尼200 mg每日两次。
- 帕克替尼获批用于血小板≤50×10^9/L的骨髓纤维化患者。
临床怎么用
- 帕克替尼可用于治疗血小板≤50×10^9/L的骨髓纤维化患者。
局限性
- PERSIST-1中帕克替尼400 mg每日一次组因出血和心脏事件过多被美国食品药品监督管理局要求临床暂停。
- PERSIST-2研究因临床暂停而突然终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis (MF) can present with symptomatic splenomegaly and/or cytopenias including thrombocytopenia. Disease-related thrombocytopenia is a poor prognostic factor with a median overall survival of less than 2 years. Currently approved JAK1/2 inhibitors have not been evaluated in patients with platelets ≤ 50 × 109/L and in fact could potentiate thrombocytopenia because of their combined JAK1/2 inhibitory activity. Pacritinib (PAC), a selective JAK2, fms-like tyrosine kinase 3, interleukin-1 receptor-associated kinase 1 multikinase inhibitor was developed to meet this unmet need. PAC was evaluated in 2 randomized phase 3 trials in the frontline setting (PERSIST-1, PAC 400 mg daily vs best available therapy) and second-line setting in patients with MF with platelets ≤ 100 × 109/L (PERSIST-2, PAC 400 mg daily or 200 mg twice daily vs best available therapy). PERSIST-1 met its primary end point; however, the development of PAC hit a brief pause because of a US Food and Drug Administration-mandated clinical hold for excess of bleeding and cardiac events in the PAC 400 mg daily arm in the PERSIST-1 study. Although the PERSIST-2 study was terminated abruptly because of this clinical hold, it met its splenic response end point and demonstrated a trend toward symptom improvement. Subsequent, diligent review of the PERSIST-1 and PERSIST-2 studies did not confirm an excess of severe bleeding or cardiac events on the PAC arm. Additionally, the dose finding PAC203 study endorsed the safety and efficacy of 200 mg twice daily, leading to the approval of PAC for the treatment of patients with MF with platelets ≤ 50 × 109/L.
引用
- Venugopal S, Mascarenhas J. The odyssey of pacritinib in myelofibrosis. Blood Adv. 2022. PMID: 35622972. doi:10.1182/bloodadvances.2022007524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。